Thrombolytic treatment of cerebrovascular disease;Terapia trombolitica en la enfermedad cerebrovascular

Revista de Neurologia

Volumn 29, Issue 12, 1999, Pages 1301-1309

  Estol, C J ^a  

^a Centro Neurol de Tratamiento/Rehab   (Argentina)

Author keywords

Cerebrovascular disorders; T PA; Therapeutic window; Thrombolytic agents; Uroquinase

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; UROKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; FIBRINOLYTIC THERAPY; HUMAN; RECANALIZATION; ACUTE DISEASE; BRAIN ISCHEMIA; REVIEW;

ACUTE DISEASE; BRAIN ISCHEMIA; CLINICAL TRIALS; HUMANS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033576534     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2912.99350     Document Type: Conference Paper

References (63)

1. Kunitz SC, Gross CR, Heyman A, et al. The pilot stroke data bank: definition, design and data. Stroke 1984; 15: 740-6.
2. Wityk RJ, Lehman D, Klag M, et al. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996; 27: 1974-80.
3. Chimowitz MI, Kokkinos J, Strong J, et al. The warfarin-aspirin intracranial disease study. Neurology 1995; 45: 1488-93.
4. Del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
5. Pessin MS, del Zoppo, Furlan AJ. Thrombolytic treatment in acute stroke: review and update of selective topics. In Moskowithz MA, Chaplain, LR, eds. Cerebrovascular diseases. Nineteenth Princeton Stroke Conference. Boston: Butterworth-Heinemann; 1995. 409-18.
6. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarctions. Neurology 1993; 43: 1298-303.
7. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951; 10: 92-4.
8. Ogata J, Yutani C, Imakita M, et al. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 1989; 20: 876-83.
9. Del Zoppo GJ, Pessin MS, Mori E, et al. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurol 1991; 11: 368-84.
10. Pessin MS, del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Pharmacol 1990; 13: 271-89.
11. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167: 1705-9.
12. Clarke RL, Cliffton EE. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol 1960; 30: 546-51.
13. Herndon RM, Meyer JS, Johnson JF, et al. Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Am J Cardiol 1960; 30: 540-5.
14. Meyer JS, Hemdon RM, Gotoh F, et al. Therapeutic thrombolysis. In Millikan CH, Siekert RG, Whisnant JP, eds. Cerebral vascular diseases. Third Princeton Conference. New York: Grune & Stratton; 1961. p. 160-77.
15. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963; 13: 927-37.
16. Atkin N, Nitzberg S, Dorsey J. Lysis of intracerebral thromboembolism with fibrinolysin. Report of a case. Angiology 1964; 15: 346-439.
17. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964; 189: 373.
18. Araki G, Minakami K, Mihara H. Therapeutic effects of urokinase on cerebral infarction. Rinsho Kenekyu 1973; 50: 3317-26.
19. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-42.
20. Abe T, Kazawa M, Naito I. Clinical effect of urokinase (60,000 units/day) on cerebral infarction-comparative study by means of multiple center double blind test. Blood Vessels 1981; 12: 342-58.
21. Nenci GG, Gresele P, Taramelli M, et al. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 1983; 34: 561-71.
22. Miyakawa T. The cerebral vessels and thrombosis. Rinsho Ketsueki 1984; 25: 1018-26.
23. Atarashi J, Otomo E, Araki G, et al. Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis. Clin Eval 1985; 13: 659-709.
24. Otomo E, Araki G, Itoh E, et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval 1985; 13: 711-51.
25. Rt-PA Acute Stroke Study Group. An open safety/efficacy trial of rt-PA in acute thromboembolic stroke: final report. Stroke 1991; 22: 153.
26. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-40.
27. Mori E, Yoneda Y, Ohkawa S, et al. Double-blind placebo-controlled trial of intravenous recombinant tissue plasminogen activator (rt-PA) in acute stroke. Neurology 1991; 41: 347.
28. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
29. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999; 340: 1781-7.
30. Caplan LR. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1999; 341: 1240-1.
31. The Multicentre Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-50.
32. Donnan GA, Davis SM, Chambers BR, et al. Trial of streptokinase in severe acute ischemic stroke. Lancet 1995; 345: 578-9.
33. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346: 1509-14.
34. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-25.
35. Hacke W, Bluhmki E, Steiner T, et al. Dichotomized efficacy end points and global end point analysis applied to the ECASS intention to treat data set. Post Hoc analysis of ECASSI. Stroke 1998; 29: 2073-5.
36. Hacke W, Kaste M, Fieschi C, et al. Randomised double blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASSII). Lancet 1998; 352: 1245-51.
37. Von Kummer R, Holle R, Meier D. Effect of training in the recognition of large ischemic lesions on CT scans obtained within 6 hours of stroke onset. Stroke 1998; 29: 310.
38. Del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988; 19: 307-13.
39. Mori E, Tabuchi M, Yoshida T, et al. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19: 802-12.
40. Theron J, Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. Am J Neuroradiol 1989; 10: 753-65.
41. Matsumoto N, Satoh N. Topical intraarterial urokinase infusion for acute stroke. In Hacke W, del Zoppo GJ, Hirshberg M, eds. Thrombolytic therapy in acute ischemic stroke. Berlin: Springer-Verlag; 1991. p. 207-12.
42. Zeumer N, Freitag HJ, Zanella F, et al. Local intraarterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (rt-PA). Neuroradiology 1993; 35: 159-62.
43. Hacke W, Zeumer H, Ferbert A, et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22.
44. Möbius E, Berg-Dammer E, Kuhne D, et al. Local thrombolytic therapy in acute basilar artery occlusion: experience with 18 patients. In Hacke W, del Zoppo GJ, Hirshberg M, eds. Thrombolytic therapy in acute ischemic stroke. Berlin: Springer-Verlag; 1991. p. 213-5.
45. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
46. Von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992; 23: 646-52.
47. Yamaguchi T, HayakawaT, Kikuchi H, et al. Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study. In Hacke W, del Zoppo GJ, Hirshberg M, eds. Thrombolytic therapy in acute ischemic stroke. Berlin: Springer-Verlag; 1991. p. 168-74.
48. Yamaguchi T, Hayakawa T, Kikuch M, for the Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double blind trial. In Del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic therapy in acute ischemic stroke. 2 ed. Berlin: Springer-Verlag: 1993. p. 59-65.
49. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-5.
50. Haley EC, Brott TG, Sheppard GL, et al. For the t-PA bridging study group. Pilot randomized trial of tissue plasminogen activator in acute stroke. Stroke 1993; 24: 1000-4.
51. Del Zoppo GJ, Higashida RT, Furlan AJ, the PROACT investigators. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4-11.
52. Furlan AJ, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 1999; 282: 2003-11.
53. Rother J, Wentz KU, Rautenberg W, et al. Magnetic resonance in vertebrobasilar ischemia. Stroke 1993; 24: 1310-5.
54. Schriger DL, Kalafut M, Starkman S, et al. Cranial computed tomography interpretation in acute stroke. JAMA 1998; 279: 1293-7.
55. Caplan LR, Mohr JP, Kistler JP. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis-not a panacea for ischemic stroke. N Engl J Med 1997; 337: 1309-10.
56. Koberda JL, Clark WM, Lutsep H, et al. Successful clinical recovery and reversal of mid-basilar occlusion in clinically brain dead patient with intraarterial urokinase. Neurology 1997; 48: (Suppl 2): A154.
57. Grotta J. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Rt-PA, the best current option for most patients. N Engl J Med 1997; 337: 1310-2.
58. Tanne D, Mansbach H, Verro P, et al. Intravenous rt-PA therapy for stroke in clinical practice: a multicenter evaluation of outcome. Stroke 1998; 29: 288.
59. Grond M, Rudolf J, Schmulling S, et al. Can the NINDS results be transferred into daily routine? Stroke 1998; 29: 288.
60. Leira EC, Davis PH, Grimsman KJ, et al. The use of thrombolytic therapy for acute stroke in community hospitals: a survey of emergency and primary care physicians in Iowa. Stroke 198; 29: 303.
61. Katzan IL, Sila CA, Furlan AJ. Community use of t-PA for acute stroke: results of the brain matters stroke management workshops survey. Neurology 1998; 50: A437-8.
62. Furlan AJ, Kanoti G. When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective. Stroke 1997; 28: 214-8.
63. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996; 94: 1167-74.